Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$3.66 - $8.22 $0 - $0
0 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$5.93 - $17.83 $0 - $0
0 New
0 $0

Others Institutions Holding HGEN

About HUMANIGEN, INC


  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Gerber Kawasaki Wealth & Investment Management Portfolio

Follow Gerber Kawasaki Wealth & Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gerber Kawasaki Wealth & Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Gerber Kawasaki Wealth & Investment Management with notifications on news.